As the founders of MyeloPro, we have devoted most of our scientific and medical careers to the understanding of myeloproliferative neoplasms (MPNs), the treatment of blood cancers and delivering state-of-the-art diagnostic tests for MPNs. The foundation of MyeloPro enables us to pursue in an industrial setting novel targeted approaches to treat MPN. Our mission is to focus MyeloPro’s research and development on finding new therapies for MPNs and MPN subtypes and improving the diagnostics of MPN. We also assist other pharmaceutical companies active in the MPN field with genetic stratification of patients entering into their clinical trials. We believe our full dedication to and sole focus on MPNs to be our greatest strength.